Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 14/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16014489 | 0.85 | BTK (0.42) | BTK | |
| SCHEMBL12503527 | 0.85 | BTK (0.53) | BTK | |
| SCHEMBL16014353 | 0.82 | BTK (0.40) | BTKALDH1A1LMNAMEN1GAA | |
| SCHEMBL17407533 | 0.74 | BTK (0.39) | HIF1ABTKALDH1A1KDM4ELMNA | |
| SCHEMBL12503526 | 0.72 | BTK (0.57) | BTK | |
| Potassium Ion SCHEMBL626696 | 0.72 | BTK (0.57) | BTK | |
| SCHEMBL10201391 | 0.71 | BTK (0.44) | BTK | |
| SCHEMBL16248113 | 0.69 | BTK (0.58) | BTK | |
| SCHEMBL611319 | 0.69 | BTK (0.57) | BTK | |
| SCHEMBL16627182 | 0.69 | BTK (0.42) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964627-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-9556147-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2964627-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002206-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| WO-2014135470-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002206-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | HIF1A 3758/4885BTK 1/4885ALDH1A1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.